Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children
GUO Ye, LIU Tian-Feng, RUAN Min, YANG Wen-Yu, CHEN Xiao-Juan, ZHANG Li, WANG Shu-Chun, LIU Fang, ZHANG Jia-Yuan, LIU Xiao-Ming, QI Ben-Quan, ZOU Yao, ZHU Xiao-Fan
Pediatric Blood Disease Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300020, China
Abstract Objective To study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor (TKI, imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children. Methods The clinical data of 53 patients aged less than 15 years when first diagnosed with Ph+ ALL between October 2008 and December 2013 were retrospectively analyzed. The patients were assigned to two groups: HR (n=26) and HR+TKI (n=27). The HR group was treated with CCLG-ALL2008 protocol (for high-risk patients). The HR+TKI group was treated with imatinib in combination with CCLG-ALL2008 protocol (for high-risk patients). Results The complete remission rate and chemotherapy induction-related mortality rate in the TKI+HR and HR groups were 100% vs 75% and 0 vs 15%, respectively. The 3-year event-free survival (EFS) rate in the HR group was (6±5)%; the 5-year EFS rate of the TKI+HR group was (52±11)%. Compared with the HR group, the TKI+HR group had no increase in the toxic responses to chemotherapy and had a decrease in the infection rate during the induction period. Conclusions Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.
About author:: 10.7499/j.issn.1008-8830.2015.08.012
Cite this article:
GUO Ye,LIU Tian-Feng,RUAN Min et al. Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children[J]. CJCP, 2015, 17(8): 819-824.
GUO Ye,LIU Tian-Feng,RUAN Min et al. Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children[J]. CJCP, 2015, 17(8): 819-824.
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia[J]. N Engl J, 2006, 354(2): 166-178.
[2]
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000, 342(14): 998-1006.
[3]
Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study[J]. J ClinOncol, 2009, 27(31): 5175-5181.
[4]
Schultz KR, Bowman WP, Aledo A, et al. Continuous dosing imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with longer term follow up: Updated Results of Children's Oncology Group (COG)AALL0031[J]. Pediatr Blood Cancer, 2010, 54: 788.
[5]
Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031[J]. Leukemia, 2014, 28(7): 1467-1471.
Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)[J]. Leukemia, 1995, 9(10): 1783-1786.
Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (CTCAE) [S][v4.03: June 14, 2010]. U.S. Department of Health and Human Services. National Institutes of Health National Cancer Institute, 2008.
[10]
Schultz KR, Prestidge T, Camitta BT. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options[J]. Expert Rev Hematol, 2010, 3(6): 731-742.
[11]
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000, 342(14): 998-1006.
[12]
Lee HJ, Tompson JE, Wang ES, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspective[J]. Cancer, 2011, 117(8): 1583-1594.
[13]
Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisonepoor response treated with double Berlin-Frankfurt-Muenster protocol II[J]. Blood, 2002, 100(2): 420-426.
[14]
Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005[J]. J Clin Oncol, 2010, 28(31): 4755-4761.
[15]
Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005[J]. Br J Haematol, 2011, 154(5): 600-611.
[16]
Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study[J]. Lancet Oncol, 2012, 13(9): 936-945.
[17]
Champagne MA, Capdeville R, Krailo M, et al. Imatinibmesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study[J]. Blood, 2004, 104(9): 2655-2660.
[18]
Jeha S, Coustan-Smith E, Pei D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Cancer, 2014, 120(10): 1514-1519.
